Pooled analysis of objective cough frequency in participants with chronic cough treated with gefapixant in two Phase 3 clinical trials (COUGH-1 AND COUGH-2)

This pooled analysis examined the effect of gefapixant versus placebo on objective cough frequency in 2044 adult patients with refractory or unexplained chronic cough enrolled in the Phase 3 COUGH-1 and COUGH-2 trials. Objective cough frequency was measured using the Vitalograph VitaloJAK recording device.